Korean J Intern Med.  2005 Jun;20(2):135-140. 10.3904/kjim.2005.20.2.135.

The Efficacy of Paclitaxel and Cisplatin Combination Chemotherapy for the Treatment of Metastatic or Recurrent Gastric Cancer: a Multicenter Phase II Study

Affiliations
  • 1Division of Oncology-Hematology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. hms@med.yu.ac.kr
  • 2Department of Internal Medicine, Daegu Catholic University Hospital, Daegu, Korea.
  • 3Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.

Abstract

BACKGROUND
Although many treatments for advanced gastric cancer have been developed, only poor treatment results have generally been obtained. We performed a prospective study on the combination chemotherapy of paclitaxel and cisplatin (PC). The primary objectives of the study were elucidating the disease response and evaluating the drug regimen's safety. METHODS: Patients with metastatic or recurrent gastric cancer received intravenous paclitaxel 175 mg/m2, and cisplatin 70 mg/m2 on day 1. This cycle was repeated every 3 weeks. RESULTS: From January 2000 to March 2004, 37 patients from 3 different hospitals were enrolled in this study. A total of 135 treatment cycles (median: 3 cycles) were administered. The responses were evaluable in 34 patients; 24 patients received this regimen as their first-line treatment for metastatic cancer and the other patients received it as their second-line treatment for recurrent cancer. The objective response rate (RR) was 26.5% (95% CI: 11.7-41.3) with two complete responses, and stable disease was observed in 41.1% of the patients. Importantly, an RR of 33.3% (95% CI: 0.6-66.0) was achieved for the eight patients who received this regimen as a first-line treatment. The median follow up duration was 14 months for all the patients, and the median time to progression was 6 months (95% CI: 1.9-10.2). The overall survival time was 8.9 months (95% CI: 7.0-11.0) with a 1-year survival rate of 18.7% (95% CI: 5.6-31.8). The most common toxicity was neutropenia. CONCLUSION: PC exhibited promising activity against gastric cancer for the previously untreated patients as a first-line treatment with an acceptable toxicity profile.

Keyword

Stomach Neoplasms; Paclitaxel

MeSH Terms

Adult
Aged
Antineoplastic Agents/*therapeutic use
Antineoplastic Agents, Phytogenic/therapeutic use
Cisplatin/*therapeutic use
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Metastasis/drug therapy
Neoplasm Recurrence, Local/*drug therapy
Paclitaxel/*therapeutic use
Prospective Studies
Safety
Stomach Neoplasms/*drug therapy/*secondary
Treatment Outcome
Full Text Links
  • KJIM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr